Ani Pharmaceuticals Inc (ANIP) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 25, 2026
Ani Pharmaceuticals Inc (ANIP)
A forensic read on Ani Pharmaceuticals Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
B · Sound & dependable
Forensic grade
Safe
Financial health
4.6
Distress distance
Clean
Earnings quality
4
Forensic signals
16.1
P / E (ttm)
14.5%
ROE
$1.7B
Market cap
0.02%
Dividend yield
43.8%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Ani Pharmaceuticals Inc earns a B (Sound & dependable) forensic quality grade, and its balance-sheet distress test reads 4.6, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by share-count dilution.
What the filings flag
+8.0%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +17% over the last 2 years to FY2025 (+8.0%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~8.0% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~14%.
4% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 4% of revenue and 22% of free cash flow in FY2025 — about $1.79 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 8.0% a year and that rate is not falling, so total profit has to grow by that much annually before any of it reaches a share. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
10.2%
FY2025
Return on invested capital.Return on invested capital is 10.2% in the latest fiscal year, against 7.8% in FY2023, having run between 0.0% and 10.2% across FY2023–FY2025 with no direction held. After-tax operating profit was $42M in FY2023 and $91M in FY2025, with operating income at 9.6% of revenue in FY2023, 0.1% in FY2024 and 12.6% in FY2025. The capital base behind it grew +66% across FY2023–FY2025, from $539M to $894M, and the return did not fall doing it, so the dollars added over that window earned at least the 7.8% the older base was already earning. FY2024's operating profit carried a $8M asset write-down that alone took about 0.6 points off that year's return; FY2024 sits between the two ends of FY2023–FY2025, so the charge shapes the path between them without moving the change across it.
-35%
Key fundamentals
Latest Revenue$883.4M
Revenue Growth YoY+43.8%
Revenue CAGR (2yr)+34.7%
Net Margin8.9%
Free Cash Flow$171.4M
Return on Equity14.5%
Debt / Equity0.57x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Ani Pharmaceuticals Inc's actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Sep 25, 2026. Forensic signals flag probability, not certainty.
FY2024→FY2025
Dividend — cut.The payout was CUT ~35% in FY2025 (from FY2024). It still returns some cash, but it is NOT the dependable, rising dividend an unbroken streak implies.